Search results
Showing 8056 to 8070 of 8246 results
A refreshed Evidence Standards Framework for Digital Health Technologies
Two exciting developments which will accelerate NICE’s efforts to deliver innovation to the health and care system faster.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.
How NICE is helping to build the role of the NHS on the global stage
Kevin Miles discusses how NICE International is working to shape and improve health and care systems at home and abroad as part of the NHS Consortium for Global Health.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
NICE's flexibility in evaluation of new health tech and fairer patient access
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.
Celebrating the people who support NICE: International Volunteer Day
Applauding the members of the public who donate their valuable experience and insight to NICE.
NICE to become single point of access for Covid-19 guidance and advice
NICE announced that it is to host a new, single point of advice on caring for people with Covid-19 and the management of Covid-19 in a variety of clinical settings.
NICE is making changes to simplify our offer to the life sciences industry.
NICE announces start of review of nusinersen Managed Access Agreement
NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen.
How we can offer a broader range of benefits for people, their families and carers
NICE has been part of a research project investigating how quality of life measures used to evaluate healthcare treatments such as drugs can be extended into areas of social care and public health.
In April 2021, the National Institute for Health Research (NIHR) launched a new rolling funding call for studies addressing NICE research recommendations.
NICE approves life-changing gene therapy for treating spinal muscular atrophy
A new one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE.
Harriet Unsworth outlines her role in updating our evidence standards framework for digital health technologies. She also explains how you can share your views as part of our consultation.
How is NICE supporting digital health technology developers?
Richard Chivers, operations manager for NICE Scientific Advice, looks at how we’re supporting digital health technology developers and helping them with some of the challenges around evidence requirements and adoption within the NHS.